Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

MKSI May 7, 2026

MKS Instruments Q1 2026 Earnings Call - AI-Driven Demand Fuels Record Revenue and Strong Q2 Outlook

MKS Instruments delivered a blistering start to 2026, reporting Q1 revenue of $1.08 billion that beat the high end of guidance, driven by a 13% year-over-year surge in semiconductor sales and a 27% ju...

  • MKS Instruments reported Q1 2026 revenue of $1.08 billion, up 15% year-over-year and beating the high end of guidance, driven by strength across all three end markets.
  • Semiconductor revenue surged 13% year-over-year to $466 million, with strong sequential growth led by vacuum products, plasma gases, and RF power solutions serving advanced DRAM, logic, and NAND applications.
  • Electronics & Packaging revenue jumped 27% year-over-year to $321 million, fueled by AI-driven demand for advanced PCB manufacturing, high-end smartphone flex drilling, and chemistry solutions.
  • +7 more takeaways
WHR May 7, 2026

Whirlpool Q1 2026 Earnings Call - Largest Price Increase in a Decade Amid Record Consumer Sentiment Drop

Whirlpool delivered a bruising first quarter, with North American demand plunging 7.4% as consumer sentiment hit a 50-year low following the outbreak of war in Iran. The company took decisive, aggress...

  • North American industry demand fell 7.4% in Q1 2026, with March down 10%, driven by a collapse in consumer sentiment to a 50-year low amid geopolitical tensions.
  • Whirlpool announced its largest price increase in over a decade, exceeding 10%, executed in two steps: a promotional price increase already in effect and a list price increase effective July 9.
  • The company revised its full-year 2026 U.S. industry demand forecast to decline by 5%, reflecting prolonged macroeconomic pressure and a lack of immediate recovery.
  • +7 more takeaways
CIM May 7, 2026

Chimera Investment Corporation Q1 2026 Earnings Call - Restructures Portfolio to Boost Dividend Coverage and Earnings Power

Chimera Investment Corporation navigated a volatile Q1 2026 marked by geopolitical shocks and shifting rate expectations, delivering $0.54 in earnings available for distribution (EAD) per share and co...

  • Chimera reported Q1 2026 Earnings Available for Distribution (EAD) of $0.54 per share, covering the $0.45 dividend by 120% and marking the ninth time in ten quarters that EAD exceeded the dividend.
  • The company redeemed eight securitizations backed by $1.5 billion in legacy re-performing loans, selling $1.2 billion and retaining $287 million to re-securitize, releasing $195 million in equity for immediate redeployment.
  • Agency RMBS allocation increased from 15% to 21% of the portfolio, while loan exposure decreased from 62% to 55%, shifting capital toward more liquid and higher-yielding assets with an estimated break-even ROE under 8%.
  • +7 more takeaways
NABL May 7, 2026

N-able Q1 2026 Earnings Call - AI Automation Expands TAM by Converting Labor-Intensive Services to Software

N-able delivered solid Q1 2026 results with ARR growing 8% in constant currency and adjusted EBITDA margin holding at 27%. The company is pivoting from a pure software vendor to an AI-driven platform ...

  • Q1 2026 ARR reached $548 million, growing 8% in constant currency and 11% on a reported basis. Total revenue came in at $134 million, beating the high end of guidance by $2 million.
  • Adjusted EBITDA margin held steady at 27%, with Q1 adjusted EBITDA of $37 million. Unlevered free cash flow was $22 million, and management raised full-year UFCF guidance to $116-$120 million.
  • Net revenue retention improved to 106% on a reported basis, driven by strong cross-sell of MDR and favorable FX impacts. Gross revenue retention also showed sequential improvement.
  • +7 more takeaways
XMTR May 7, 2026

Xometry Q1 2026 Earnings Call - Record Growth and Strategic Siemens Partnership Drive Acceleration

Xometry reported record Q1 2026 results with revenue accelerating 36% year-over-year to $205 million, driven by a 40% surge in marketplace sales and expanding margins. The company raised its full-year...

  • Revenue grew 36% year-over-year to $205 million, with a 600 basis point acceleration from Q4, marking three consecutive quarters of accelerating growth.
  • Marketplace revenue surged 40% year-over-year, outpacing overall growth and driven by strong enterprise adoption and expanding wallet share.
  • Active buyers increased 20% year-over-year to 85,581, with net additions of 3,760, the highest in nine quarters, reflecting successful product-led growth strategies.
  • +9 more takeaways
BOBS May 7, 2026

Bob's Discount Furniture Q1 2026 Earnings Call - Resilient Growth Amidst Macro Headwinds

Bob's Discount Furniture delivered an 8.5% year-over-year sales increase in Q1 2026, driven by new store expansion and a 1.2% comparable sales growth, despite adverse winter weather and a challenging ...

  • Total net sales increased 8.5% year-over-year to $578.1 million, driven by new store openings and 1.2% comparable store sales growth.
  • Adjusted EBITDA margin came in at 6.5%, slightly ahead of management expectations, despite extreme weather disruptions.
  • Customers are trading up from the 'good' to 'better' price tiers, with broad-based strength across motion, bedroom, and mattress categories.
  • +7 more takeaways
LSAK May 7, 2026

Lesaka Technologies Q3 FY2026 Earnings Call - Consumer Division Drives Record Profitability While Merchant Transformation Nears Completion

Lesaka Technologies delivered a record-breaking Q3 FY2026, with group adjusted EBITDA surging 45% year-over-year to ZAR 337 million and adjusted earnings jumping 246% to ZAR 148 million. The Consumer ...

  • Group adjusted EBITDA rose 45% to ZAR 337 million, marking an all-time quarterly high and hitting the top end of guidance.
  • Adjusted earnings surged 246% to ZAR 148 million, with adjusted EPS jumping from ZAR 0.52 to ZAR 1.80.
  • Consumer division EBITDA grew 81% to a record ZAR 213 million, fueled by a 33% year-over-year increase in lending originations to ZAR 856 million.
  • +7 more takeaways
LNC May 7, 2026

Lincoln Financial Group Q1 2026 Earnings Call - Seventh Consecutive Quarter of Adjusted Operating Income Growth Driven by Strategic Shift to Spread-Based Products

Lincoln Financial Group delivered another quarter of disciplined execution, posting a 16% year-over-year increase in adjusted operating income for the seventh consecutive quarter. The results undersco...

  • Adjusted operating income grew 16% year-over-year, marking the seventh consecutive quarter of growth and signaling strong execution of the company's strategic priorities.
  • Fixed indexed annuity (FIA) sales surged over 90% year-over-year, reflecting a successful pivot away from price-sensitive MYGA products toward differentiated, spread-based offerings.
  • Group Protection operating income rose 11% year-over-year, with margin expanding 60 basis points to 8%, driven by favorable Group Life underwriting and disciplined pricing.
  • +7 more takeaways
EPR May 7, 2026

EPR Properties Q1 2026 Earnings Call - Accelerating Investment and Upside Guidance on Experiential Resilience

EPR Properties delivered a 5.9% year-over-year increase in FFO as adjusted per share in Q1 2026, driven by strong experiential spending and the strategic acquisition of a 7-park Six Flags portfolio. T...

  • FFO as adjusted per share grew 5.9% year-over-year to $1.26, with AFFO per share rising 6.6% to $1.29.
  • Full-year 2026 FFO guidance increased to $5.37-$5.53 per share, representing 6.5% growth at the midpoint.
  • Investment spending guidance raised to $500 million-$600 million, the highest level since the pandemic.
  • +7 more takeaways
IOVA May 7, 2026

Iovance Biotherapeutics Q1 2026 Earnings Call - AMTAGVI Demand Surges as Iovance Pivots to In-House Manufacturing and Pipeline Expansion

Iovance Biotherapeutics delivered a strong first quarter of 2026, with revenue growing 45% year-over-year to $71 million, driven by robust AMTAGVI demand and strategic cost discipline. The company suc...

  • Q1 2026 revenue reached $71 million, a 45% year-over-year increase, fueled by $60 million in AMTAGVI sales and $11 million in Proleukin revenue.
  • AMTAGVI production is now exclusively in-house at Iovance’s internal facility, ICTC, following a temporary capacity reduction for maintenance upgrades, with management confident in uninterrupted supply.
  • Second-quarter revenue guidance is raised to $86 million-$88 million, with AMTAGVI revenue expected to hit $79 million-$81 million, marking a 23% increase over the previous record quarter.
  • +12 more takeaways